Janux Therapeutics, Inc. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Janux Therapeutics, Inc. (JANX) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $581.42 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $581.42M.
- 2026-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $496.51M.
- 2025-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $470.41M.
- 2025-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $485.26M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2026-06-30 | $581.42M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $496.51M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $470.41M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $485.26M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $467.58M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $409.44M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $172.25M 10-K · filed 2026-02-26 |
| 2024-09-30 | $182.40M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $181.60M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $174.79M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $210.65M 10-K · filed 2025-02-27 |
| 2023-09-30 | $196.48M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $197.80M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $260.76M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $238.16M 10-K · filed 2024-03-08 |
| 2022-09-30 | $270.02M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $290.90M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $267.12M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $291.27M 10-K · filed 2023-03-10 |
| 2021-09-30 | $303.13M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |